Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

9.530
-0.285-2.90%
Volume:38.10M
Turnover:372.07M
Market Cap:109.80B
PE:23.96
High:10.040
Open:9.880
Low:9.520
Close:9.815
52wk High:10.720
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.41
T/O Rate:0.33%
Dividend:0.34
Dividend Rate:3.54%
EPS(LYR):0.398
ROE:20.90%
ROA:10.70%
PB:2.49
PE(LYR):23.96
PS:2.99

Loading ...

Cspc Pharmaceutical's Recombinant Herpes Zoster Vaccine (Sys6052) Obtains FDA Clinical Trial Approval in U.S.

Reuters
·
Sep 29

CSPC Pharmaceutical - Phase Ib Trial to Evaluate Jmt206 Injection as Monotherapy or with Semaglutide in Obesity

THOMSON REUTERS
·
Sep 29

CSPC Pharmaceutical - Phase Ib Clinical Trial of Jmt206 Injection for Weight Management in Adult Patients Initiated at First Study Centre in China

THOMSON REUTERS
·
Sep 29

CSPC Pharma Gets China Nod for Tumor Drug Trial

MT Newswires Live
·
Sep 28

CSPC Pharmaceutical - Pharma's Sys6077 Injection Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Sep 28

CSPC PHARMA: BlackRock, Inc. Disposes of Shares, Long Position Falls to 4.99%

HK Disclosure
·
Sep 28

Regulator Clarifies Insurers' Hong Kong Stock Connect ETF Investment Rules; Crealights' Southbound Stake Rises to 4.2%

Stock News
·
Sep 25

CSPC Pharmaceutical Says Phase III Trial of Becotatug Achieves Positive Topline Results

Reuters
·
Sep 24

CSPC Pharma's Phase III Trial of Lung Cancer Drug Combo Achieves Positive Topline Results

MT Newswires Live
·
Sep 24

CSPC Pharma's JMT101 Combined with Osimertinib Achieves Positive Topline Results in Phase III Trial for First-Line Treatment of EGFR ex20ins NSCLC

Stock News
·
Sep 24

CSPC Pharma Reports Positive Phase III Results for Becotatug-Osimertinib Combo in EGFR Exon 20 NSCLC

Bulletin Express
·
Sep 24

CSPC Pharmaceutical - Phase Iii Trial of Becotatug (Jmt101) with Osimertinib Achieves Positive Topline Results

THOMSON REUTERS
·
Sep 24

CSPC Pharm Begins Phase III Breast Cancer Drug Trial

MT Newswires Live
·
Sep 24

CSPC Pharmaceutical - Pharma Initiates Phase Iii Trial of Hb1801 for Advanced Breast Cancer in China

THOMSON REUTERS
·
Sep 24

CSPC Pharmaceutical Group Stock Slips 3.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 24

Movement Alert|CSPC PHARMA Falls 3.01% in Regular Trading, Trading at HK$9.34

Market Focus
·
Sep 24

Second-Generation Leaders Ascend in China's Pharma Sector, Poised to Steer Industry Transformation

Deep News
·
Sep 22

2026 Private Sector Top 500: Three Major Firms Slide Down The Rankings

Deep News
·
Sep 22

CSPC Pharma: BlackRock, Inc. Acquires Shares, Long Position Rises to 5.0%

HK Disclosure
·
Sep 22

CSPC Pharmaceutical Group Stock Climbs 1.1% in Hong Kong, Outperforms Competitors

Dow Jones
·
Sep 22